Full Text
CV2 COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS ATORVASTATIN, SIMVASTATIN, AND PRAVASTATIN FROM A CANADIAN HEALTH CARE PERSPECTIVE

Abstract

Authors

M Costa-Scharplatz B Beamer T Frial SK Gandhi

Back to Volume 10, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×